Supplementary Files
Keywords
Inhalable allergens
Subcutaneous immunotherapy
Abstract
Background: Specific immunotherapy is a treatment aimed at modifying the course of the allergic disease, with which important immunological and clinical changes are achieved.
Objective: To assess the effectiveness and safety of subcutaneous immunotherapy in patients diagnosed with respiratory allergies in the University Hospital of Puebla, Mexico.
Methods: A longitudinal, analytic, quasi-experimental study. The study was carried out with patients aged four to sixty-five years, diagnosed with allergic rhinitis or asthma, with sensitization to aeroallergens, in whom immunotherapy was started. For the effectiveness assessment, the Control of Allergic Rhinitis and Asthma Test (CARAT) was used. Safety was assessed through Portnoy’s Questionnaire Survey of Adverse Reactions.
Results: 59 patients were included: 72.9% were female; 23.7% of them were diagnosed with allergic rhinitis and asthma, and 76.3% were diagnosed with allergic rhinitis. The comparison of averages of the CARAT questionnaire at the beginning of the treatment and after four months of follow up showed a statistically significant positive development. An incidence of adverse local reactions of 9.03% was found; no adverse systemic reactions were reported.
Conclusions: The assessed scheme of subcutaneous immunotherapy got to significantly decrease the asthma symptoms and AR symptoms, with a desirable safety profile.
References
Eifan AO, Calderón MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther. 2016;13(11):1543-1556. DOI 10.1517/14712598.2013.844226
Roche A, Wise SK. Subcutaneous immunotherapy. Int Forum Allergy Rhinol. 2014;4(Suppl 2):51-54. DOI: 10.1002/alr.21382
Moral A, Pola J, Feo F. Principales alérgenos de interior. En: Peláez A, Dávila I, editores. Tratado de alergología. España: Ergon; 2007.
Larenas-Linnemann D, Salas-Hernández J, Vázquez-García JC, Ortiz-Aldana I, Fernández-Vega M, Del Río-Navarro BE, et al. Guía Mexicana del Asma 2017. Rev Alerg Mex. 2017;64(Supl 1): s11-s128. DOI: 10.29262/ram.v64i0.272
Global strategy for asthma management and prevention. EE. UU.: Global Initiative for Asthma; 2016. Disponible en: https://ginasthma.org/wp-content/uploads/2019/04/wmsGINA-2017-main-report-final_V2.pdf
Larenas-Linnemann D, Mayorga-Butrón JL, Sánchez-González A, Ramírez-García A, Medina-Ávalos M, Figueroa-Morales MA, et al. ARIA México 2014. Adaptación de la Guía de Práctica Clínica ARIA 2010 para México. Metodología ADAPTE. Rev Alerg Mex. 2014;61(Supl 1):S3-S116. Disponible en: http://revistaalergia.mx/ojs/index.php/ram/article/view/52/94
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8-160. DOI: 10.1111/j.1398-9995.2007.01620.x
Passalacqua G, Canonica GW. Allergen immunotherapy: history and future developments. Immunol Allergy Clin North Am. 2016;36(1):1-12. DOI: 10.1016/j.iac.2015.08.001
Fitzhugh DJ, Lockey RF. History of immunotherapy: the first 100 years. Immunol Allergy Clin North Am. 2011;31(2):149-157. DOI: 10.1016/j.iac.2011.03.003
Nelson H. Injection immunotherapy for inhalant allergens. En: Adkinson F, Bochner B, Burks W, Busse W, Holgate S, Lemanske R, et al., editores. Middleton’s allergy principles and practice. EE. UU.: Elsevier; 2014.
Cardona R, Rojas W. Mecanismos básicos de las alergias. En: Rojas MW, Anaya CJM, Aristizabal BB, et al, editores. Inmunología de rojas. Colombia: Corporación para Investigaciones Biológicas; 2015.
Martín-Muñoz M, Pineda F, Muiños T, Fontan M, Nevot S, Bosque M, et al. Changes in IL-10 and specific antibodies associated to successful dermatophagoides pteronyssinus immunotherapy in children during the first year of treatment. Allergol Immunopathol (Madr). 2013;41(1):4-10. DOI: 10.1016/j.aller.2011.12.005
Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo controlled, double blind, double dummy study. Int Arch Allergy Immunol. 2012;157(3):288-298. DOI: 10.1159/000327566
Senti G, Kündig TM. Novel delivery routes for allergy immunotherapy: intralymphatic, epicutaneous, and intradermal. Immunol Allergy Clin North Am. 2016;36(1):25-37. DOI: 10.1016/j.iac.2015.08.006
Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol. 2010;125(3):569-574. DOI: 10.1016/j.jaci.2009.10.060
Karakoc-Aydiner E, Eifan AO, Baris S, Gunay E, Akturk H, Akkoc T, et al. Long-term effect of sublingual and subcutaneous immunotherapy in dust mite–allergic children with asthma/rhinitis: a 3-year prospective randomized controlled trial. J Investig Allergol Clin Immunol. 2015;25(5):334-342. Disponible en: http://www.jiaci.org/issues/vol25issue5/3.pdf
Lee JH, Kim SC, Choi H, Jung CG, Ban GaY, Shin Y, et al. Subcutaneous immunotherapy for allergic asthma in a single center of Korea: efficacy, safety and clinical response predictors. J Korean Med Sci. 2017;32(7):1124-1130. DOI: 10.3346/jkms.2017.32.7.1124
Frew A, Smith H. Inmunoterapia específica de alérgeno. En: O’Hehir R, Holgate S, Sheikh A, editores. Middleton. Alergología esencial. México: Elsevier; 2017.
Azevedo P, Correia-De Sousa J, Bousquet J, Bugalho-Almeida A, Del Giacco SR, Demoly P, et al. Control of Allergic Rhinitis and Asthma Test (CARAT): dissemination and applications in primary care. Prim Care Respir J. 2013;22(1):112-126. DOI: 10.4104/pcrj.2013.00012
Fonseca JA, Nogueira-Silva L, Morais-Almeida M, Azevedo L, Sa-Sousa A, Branco-Ferreira M, et al. Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthma. Allergy. 2010;65(8):1042-1048. DOI: 10.1111/j.1398-9995.2009.02310.x
Álvarez-Cuesta E, Bousquet J, Canonica GW Durham SR, Malling HJ, Valovirta E, et al. Standards for practical allergen-specific immunotherapy. Allergy. 2006;61(Suppl 82):1-20. DOI: 10.1111/j.1398-9995.2006.01219_1.x
Rottem M, Egbarya A. Subcutaneous immunotherapy in Northern Israel: efficacy and safety. Isr Med Assoc J. 2014;16(9):539-543. Disponible en: https://www.ima.org.il/FilesUpload/IMAJ/0/92/46407.pdf
Larenas-Linnemann D, Ortega-Martell J, Del Río-Navarro B, Rodríguez-Pérez N, Arias-Cruz A, Estrada A, et al. Guía Mexicana de Práctica Clínica de Inmunoterapia 2011. Rev Alerg Mex. 2011;58(1):16-21. Disponible en: https://www.elsevier.es/es-revista-revista-alergia-mexico-336-articulo-guia-mexicana-practica-clinica-inmunoterapia-X0002515111209882
Caminati M, Dama AR, Djuric I, Montagni M, Schiappoli M, Ridolo E, et al. Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety. Expert Rev Clin Immunol. 2015;11(2):233-245. DOI: 10.1586/1744666X.2015.988143
Erekosima N, Suarez-Cuervo C, Ramanathan M, Kim JM, Chelladurai Y, Segal JB, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope. 2014;124(3):616-627. DOI: 10.1002/lary.24295
Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010(8):CD001186. DOI: 10.1002/14651858.CD001186.pub2
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2019 Revista Alergia México